The tweet was deleted by the author.
But we saved everything 🙂.
Tyra Biosciences attracted industry attention during the IBCG26 Annual Retreat, where the company engaged with attendees over new developments shaping the future of bladder cancer treatment.
The firm presented its latest research in IR non-muscle invasive bladder cancer (NMIBC) and participated in discussions with scientific and clinical leaders. Tyra Biosciences continues to focus on innovative approaches in bladder cancer care.
View post on X Loading...
Tyra Biosciences previously began the SURF302 trial to evaluate a new therapy for intermediate-risk non-muscle invasive bladder cancer. The company has also launched the BEACH301 study to explore selective FGFR3 inhibition in achondroplasia. Both studies reflect Tyra’s ongoing focus on targeted treatment innovation.